Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities (Q46098021)

19 December 2017

title

Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities (English)

1 reference

19 December 2017

1 reference

Richard D O'Connor

1

1 reference

19 December 2017

Bhash Parasuraman

series ordinal

2

1 reference

19 December 2017

Craig Roberts

series ordinal

3

1 reference

19 December 2017

Christopher Leibman

series ordinal

4

1 reference

19 December 2017

publication date

1 August 2006

1 reference

19 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

19 December 2017

volume

97

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

236-243

1 reference

19 December 2017

Trends in the cost of illness for asthma in the United States, 1985-1994

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

The burden of asthma with specific reference to the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

National trends in asthma visits and asthma pharmacotherapy, 1978-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Spinal versus epidural anaesthesia for caesarean section

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

The central role of the propensity score in observational studies for causal effects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Estimating causal effects from large data sets using propensity scores

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Any casualties in the clash of randomised and observational evidence?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Randomized, controlled trials, observational studies, and the hierarchy of research designs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

A comparison of observational studies and randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

"Real-world" effectiveness of daily controller medicine in children with mild persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960020-8

7 January 2021

10.1016/S1081-1206(10)60020-8

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017